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ABSTRACT
Introduction Skin barrier development and dysfunction in 
premature and mature newborns is important for the risk 
of atopic dermatitis (AD).
Methods and analysis The Barrier dysfunction in Atopic 
newBorns studY (BABY) Cohort is a prospective birth 
cohort study of 150 preterm children (gestational age (GA) 
below 37+0) and 300 term children (GA 37+0 to 41+6). 
Skin barrier is assessed through transepidermal water 
loss, tape stripping, Raman- spectroscopy and microbiome 
sampling. Clinical examinations are done and DNA from 
buccal swabs is collected for genetic analyses. Thymus 
size is assessed by ultrasound examination. Information 
on pregnancy, delivery, parental exposures and diseases 
are collected, and structured telephone interviews are 
conducted at 18 and 24 months to assess exogenous 
exposures in the child and onset of AD. Hanifin and Rajka 
criteria as well as The UK Working Party's Diagnostic 
Criteria for Atopic Dermatitis are used to diagnose AD. 
Severity of AD is assessed using the Eczema Area and 
Severity Index (EASI) and Patient Oriented Eczema 
Measure (POEM).
Ethics and dissemination The study is approved by 
the scientific Ethical Committee of the Capital Region (H-
16042289 and H-16042294).
Outcomes will be presented at national and international 
conferences and in peer- reviewed publications.
INTRODUCTION
Atopic dermatitis (AD) is a chronic and 
relapsing, inflammatory skin disease, charac-
terised by dry and itchy skin that affects up to 
20% of children in Northern Europe.1 About 
60% to 80% develop the disease in their 
first 2 years of life, and children with early 
onset are at increased risk of having severe 
and persistent disease.2 3 The risk of AD is 
increased in children of parents with atopic 
disorders such as AD, asthma and allergic 
rhinitis.4–6
Genetic and environmental risk factors 
contribute to the development of AD through 
skin barrier dysfunction and immune dysreg-
ulation.2 While loss- of- function mutations in 
the filaggrin gene (FLG) have been identified 
as the strongest genetic risk factor for AD,7 
genome- wide association studies have only 
identified a relatively small proportion of 
the genetic risk effect.8 The inflammation in 
AD is characterised by overexpression of Th2 
cytokines, including interleukin (IL)-4 and 
IL-13.9 That, together with IL-1, may lead to 
increased secretion of thymic stromal lymph-
opoietin, decreased epidermal antimicrobial 
peptides and filaggrin levels, which, in turn, 
can worsen skin inflammation and epidermal 
barrier functions.10 Changes in the skin 
microbiome is also associated with worsening 
of AD, showing reduced bacterial diversity11 
and increased colonisation with Staphylococcus 
aureus.12
While several environmental risk factors 
have been identified, for example, winter 
birth and exposure to hard domestic 
water, this has not yet led to prophylactic 
solutions.13 Interestingly, the risk of AD 
is decreased in premature newborns and 
infants undergoing heart surgery, which 
often includes partial or total thymectomy, 
perhaps due their reduced number of 
total lymphocytes and circulating T- cells, 
resulting in an inappropriate immune 
response to antigens encountered in the 
skin.14–16
Strengths and limitations of this study
 ► This is a Danish prospective birth cohort study as-
sessing skin barrier functions and risk factors for 
atopic dermatitis.
 ► The study includes both preterm and term newborns 
from the general population.
 ► Repeated and comprehensive measurements of 
skin barrier will be performed at several time points.
 ► A limitation is the lack of blood measurements as 
this study is strictly non- invasive.
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There is a need for birth cohort studies that closely 
examine the skin of newborns at several time points to 
identify infants at risk of developing AD early in life. The 
Barrier dysfunction in Atopic newBorns studY (BABY) 
Cohort is a prospective birth cohort study that inves-
tigates early skin barrier development in preterm and 
term newborns to identify early prognostic skin barrier 
changes for the development of AD.
OBJECTIVES
Primary objective
To identify early predictors of AD during the first 2 years 
of life, including skin barrier dysfunction and exogenous 
exposures during pregnancy and in infancy. The study will 
assess patient and parental characteristics, family history 
of atopic comorbidities, exposures during pregnancy and 
in infancy, and skin barrier function and development.
Secondary objectives
To closely describe the normal skin barrier development, 
including immune activity and skin microbiome, in 
preterm and term newborns during the first 2 years of life.
METHODS AND ANALYSIS
Study population and setting
The BABY Cohort is an ongoing prospective and obser-
vational birth cohort study recruiting 150 preterm and 
300 term newborn infants. Recruitment began in August 
2017. Parents of eligible children are recruited at the 
maternity and neonatal wards at Rigshospitalet, Copen-
hagen and Nordsjællands Hospital, Hillerød, Denmark. 
Children eligible for enrolment are preterm newborns 
(gestational age (GA) below 37+0), excluding preterm 
newborns with severe congenital abnormality or condi-
tions affecting their life expectancy, and full- term healthy 
singleton newborns (GA 37+0 to 41+6), excluding mature 
newborns receiving antenatal steroids for fetal lung matu-
ration. Children with parents unable to communicate in 
Danish are excluded, since it is not possible to use (for 
practical and financial reasons) interpreters right after 
birth, given that we have to be very flexible and recruit at 
odd hours. Children are included independent of their 
hereditary risk for AD
Cohort design
All study procedures are summarised in figures 1 and 2, 
and each component of the visit is detailed below. Preterm 
children are scheduled for two study visits: during the 
first 31 days of life and approximately 2 months after 
their scheduled due date (figure 1). Term children are 
scheduled for four study visits: during the first 3 days 
of life and approximately at 2, 6 and 12 months of age 
(figure 2). Many prematurely born children continue to 
have many hospital visits after their discharge, and many 
of the families live far away from the hospital, that is, 
other parts of Denmark. Therefore, preterm children are 
only scheduled to participate in one follow- up visit. We 
can therefore only make certain comparisons across the 
two groups.
If a child develops AD during the first 2 years of life, 
an additional follow- up visit is performed. Overall, all 
children are recruited and examined as soon as possible 
after their delivery. Very prematurely born children often 
receive intensive medical care, and we wait until the child 
is stable to perform the examinations.
For all study visits, the time of the study visit is regis-
tered, to be able to adjust for any effects that occur due 
to age differences. All parents participate in a structured 
telephone interview when the child is 18 and 24 months 
old. All study visits are conducted by trained medical 
doctors.
Baseline interview
During the first study visit, parents are interviewed to 
obtain information about the pregnancy and birth, 
including the type of delivery and maternal intrapartum 
antibiotic treatment. Furthermore, information about 
GA at birth, weight, height and head circumference, 1 
and 5 min APGAR scores, and medical treatment at the 
neonatal ward is obtained.
Study interview
At every study visit, we obtain detailed information about 
the child’s health, vaccination status, method of feeding, 
admittance to hospital, medical treatments, bathing 
habits and skin care.
Parental questionnaires
Parents complete an online questionnaire on family 
structure, residential situation, pet exposure, occupa-
tion, maternal exposures during pregnancy, smoking and 
drinking habits, history about current and previous skin 
diseases, and atopic diseases in the family.
Telephone interviews
At 18 and 24 months, parents participate in a structured 
telephone interview about the child’s health, vaccina-
tion status, method of feeding, admittance to hospital, 
medical treatments, bathing habits, skin care, ultraviolet 
exposures and AD assessment using a modification to the 
UK Working Party's Diagnostic Criteria for Atopic Derma-
titis, with parental assessment of visible flexural dermatitis 
in the elbows or knees.17 If AD is diagnosed during the 
telephone interview, an extra study visit in the clinic is 
scheduled.
Anthropometric measures
At the first visit, birth information on height, weight and 
head circumference is retrieved from the birth record. 
At all follow- up visits, anthropometric measurements are 
made. A digital weight scale is used to record weight in 
kg without clothing and diaper. Height and head circum-
ference are measured in cm using a flexible non- elastic 
measuring tape.
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Skin barrier measurements
Transepidermal water loss
During all study visits, transepidermal water loss (TEWL) 
is assessed using a portable, closed condenser- chamber 
device (AquaFlux model AF200, Biox Systems Ltd, UK).18 
TEWL is measured three times on the same skin area 
located on the central part of the volar forearm. No pref-
erence is given to the left or right arm but depends on 
how the baby is positioned.
Natural moisturising factors
Using a custom- built device, the level of natural moistur-
ising factors (NMF) is measured on the thenar region 
using confocal Raman spectroscopy (RiverD International 
B.V., Rotterdam, The Netherlands).19–21 Three values are 
recorded at all study visits, except the first study visit for 
the premature children. The thenar region of the child’s 
hand is placed on the device for approximately 60 s. Scat-
tered light is sent towards the skin surface, exiting the 
molecules in the skin. Each molecule represents a specific 
spectrum of light, and the specific composition of mole-
cules is thereby represented in the returned spectrum 
of light.20 Again, the most accessible hand is measured, 
which, in turn, depends on the child’s posture at the time 
of examination.
Superficial stratum corneum sampling
During all study visits, stratum corneum (SC) is collected 
by tape stripping as previously described.22 23 Eight 
consecutive tape stripping discs (22 mm) D- squame 
(CuDerm, Dallas, Texas, USA) are applied on the skin 
followed by standardised pressure applied by a D- squame 
Figure 1 Scheduled investigations for preterm children in the BABY Cohort. AD, atopic dermatitis; BABY, Barrier dysfunction 
in Atopic newBorns studY; mo, months; TEWL, transepidermal water loss.
by copyright.
 o
n
 August 31, 2020 at Kobenhavns Universitets Bibliotek. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033801 on 12 July 2020. Downloaded from 
4 Gerner T, et al. BMJ Open 2020;10:e033801. doi:10.1136/bmjopen-2019-033801
Open access 
pressure application pen for 5 s and gently removed with 
tweezers. Tapes are stored at −80°C immediately after 
sampling. Preterm infants have SC collected from the 
skin between the shoulder blades, and at 2 months of age 
from the cheek as well. Term infants have SC collected 
from cheek skin and the dorsal surface of the hand. No 
preference is given to the left or right side but depends 
on the positioning of the child. If a child develops AD, SC 
is collected from the dorsal surface of the hand and from 
a lesional skin site, preferably from the cheek, otherwise 
from a skin site with the most severe AD. SC samples 
are analysed for biomarkers of the immune response by 
multiplex immuno- assays, NMF using a liquid chromatog-
raphy previously described by Kezic et al22 and corneocyte 
surface morphology by atomic force microscopy.24
Clinical skin assessment
A complete examination of the skin is performed at 
each study visit to describe the normal skin barrier 
development.
Size, number and location of both congenital and 
acquired naevi are registered. Studies and meta- analysis 
have shown that the number of naevi is inverse with AD. 
However, we are not aware of prospective data collection. 
The palm of the hand is photographed to assess skin 
hyperlinearity at 2 months of age and in case the child 
develops AD.
Atopic dermatitis assessment
The skin is evaluated for signs of AD at each study visit. 
A diagnosis of AD is initially given by a physician and is 
subsequently diagnosed clinically using the diagnostic 
criteria of Hanifin and Rajka except for IgE levels and 
subcapsular cataract.25 AD severity is assessed using the 
Eczema Area and Severity Index (EASI).26 During all 
following visits, AD severity is assessed using EASI and 
Patient Oriented Eczema Measure (POEM) tool27 and 
treatment for AD is recorded. As mentioned, during the 
structured telephone interviews, AD is diagnosed using 
The UK Working Party's Diagnostic Criteria for Atopic 
Dermatitis.17
Genetics
Buccal swabs (Isohelix, Harrietsham, UK) are used 
to collect DNA to screen for the most common FLG 
mutations in Northern European populations (R501X, 
Figure 2 Scheduled investigations for term children in the BABY Cohort. AD, atopic dermatitis; BABY, Barrier dysfunction in 
Atopic newBorns studY; mo, months; TEWL, transepidermal water loss.
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2282del4 and R2447X)28 by TaqMan genotyping assay, a 
routine analysis in our biochemical department, and for 
single nucleotide polymorphisms. For both analyses, the 
cheek mucosa is rubbed for 60 s with a swab and stored at 
−80°C until analysis.
Skin swabs
During all study visits, a bacterial swab is collected from 
the cheek skin (ESwab Collection and Transport System, 
Copan Italia, Brescia, Italy) and cultured for bacterial 
growth by routine methodology at the Department of 
Microbiology, Herlev and Gentofte Hospital, Denmark. 
Only samples positive for β-haemolytic streptococci 
isolates (groups A, B, C and G) or S. aureus have antimicro-
bial susceptibility testing performed and are subsequently 
stored at −80°C for future analyses. In preterm children, 
skin microbiome is collected from the lumbar area of 
the back at first visit, and from cheek and lumbar area 
at 2 months of age. Skin microbiome samples (Isohelix, 
Harrietsham, UK) are collected from cheek and dorsal 
surface of the hand in term children. If a child develops 
AD, skin microbiome is also collected from a lesional skin 
site, preferably from the cheek, otherwise from the most 
severe AD lesion. Skin swabs are rubbed on the skin for 
60 s and are immediately stored at −80°C until analysis.
Ultrasound
During all study visits, ultrasound examination is 
performed to visualise the thymus gland and measure its 
size. The thymus index is defined as the multiplication 
of the two measurements and represents an estimate of 
the thymic volume.29 The largest transverse diameter of 
the thymus is measured in a horizontal scan plane and 
the area of the largest lobe is measured in a sagittal scan 
plane. Both measurements are performed twice. The best 
images with a full visualisation of the gland are selected by 
a trained radiologist. Measurements are performed with 
a transportable LOGIQ V2 ultrasound system with a 2 to 
5.5 MHz C4- RS transducer (GE Healthcare, Milwaukee, 
Wisconsin, USA).
Study settings
At each visit, air humidity, outdoor and indoor tempera-
ture is registered.
Sample size estimation
The sample size calculation was based on including 
preterm and mature children in a 1:2 ratio. The power 
calculation was based on an expected prevalence of AD 
in 20% of the cohort population, assessing changes in 
NMF, which is one of multiple important endpoints in 
our study. Based on a previous study, where adult controls 
had an NMF of 0.095±0.029,30 we hypothesised a 12% 
change in NMF in newborns developing AD compared 
with children without developing AD. Using a two- sided 
parametric test with an alpha of 5% and a power of 80%, 
we calculated at sample size of 366 children. In order to 
account for possible drop- outs, and the intention to study 
many other predictors for AD and skin barrier function 
in general, we decided on a study population of 450 
participants in total, that is, 150 preterm and 300 mature 
children.
Data management
Study data are collected and entered directly into an 
online REDCap (Research Electronic Data Capture) 
database hosted at the Capital Region of Denmark.
Patient and public involvement
Patients and the public were not involved in the design 
of the study. All participants will be acknowledged and 
thanked for their contribution in future publications.
STRENGTHS AND LIMITATIONS
The major strength of this birth cohort study is the exten-
sive and repeated skin barrier measurements. We will 
examine the skin barrier with multiple methodologies, 
including Raman spectroscopy, TEWL and SC biomarkers. 
We will collect DNA and bacteria for genetic and skin 
microbiome analyses at several time points, increasing 
the chance of finding a pathogenic role. We will include 
both preterm and term newborns, allowing us to study 
the immature skin barrier and thymus in a large subset 
of children. We will use internationally accepted defini-
tions to diagnose AD and assess severity.25 26 Collectively, 
the BABY cohort will cover a wide range of parameters 
with potential importance for the development of AD. 
Since approximately 80% of AD patients develop their 
disease within the first 2 years of life, we expect to identify 
children with both transient and more established AD, as 
well as being able to differentiate between early features 
and predictors. Furthermore, we already now plan for 
future follow- up studies on skin barrier functions, AD and 
allergic diseases in this birth cohort.
A potential limitation of the BABY Cohort is that all 
term children are recruited from Copenhagen only, 
possibly limiting the generalisability of the study to more 
rural areas. While we will register ambient room condi-
tions, including air humidity and indoor and outside 
temperature, seasonal and climatic variations, which 
affect TEWL measurements. Since bathing habits prior 
to study visits are not standardised, but only registered, 
this might impact our skin barrier assessments. Children 
receiving incubator therapy have all measurements made 
directly in the incubator and the ambient conditions are 
recorded. As the study is strictly non- invasive, we will not 
make any blood measurements, and can therefore not 
assess the possible role of systemic inflammation. Due to 
our study design, we cannot discriminate clearly between 
early features and predictors. A concern in cohort studies 
is that participants may be lost to follow- up. This is espe-
cially a concern for the premature children with many 
potential comorbidities who are recruited from Rigshos-
pitalet, a highly specialised department responsible for 
treatment of all extremely premature children in eastern 
Denmark. To keep track of the included families, we 
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gather contact information of both parents and contact 
them prior to follow- up visits. However, in case a family 
withdraws from the study, the date and reason for with-
drawal will be recorded.
ETHICS AND DISSEMINATION
The study is approved by the scientific Ethical Committee 
of the Capital Region (H-16042289 and H-16042294) and 
the local data protection agency (ID- no.: HGH-3017–040, 
I- suite no.:05578). Both parents or guardians will give 
written informed consent prior to entry to the study.
The BABY Cohort is conducted in accordance with the 
Declaration of Helsinki. All relevant study results will be 
presented in peer- reviewed publications and presented at 
national and international conferences.
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